Last reviewed · How we verify
NCT02273336
Comprehensive Genomic Analysis in Tissue and Blood Samples From Young Patients With Lung Cancer
trial testing cytology specimen collection procedure in Non-small Cell Lung Cancer in 40 participants. Completed in 8 September 2020.
8 August 2020
Quick facts
| Lead sponsor | University of Southern California |
|---|---|
| Status | Completed |
| Study type | OBSERVATIONAL |
| Enrollment | 40 |
| Start date | 22 July 2014 |
| Primary completion | 8 August 2020 |
| Estimated completion | 8 September 2020 |
| Sites | 2 locations across United States |
Drugs / interventions tested
- cytology specimen collection procedure
- laboratory biomarker analysis — full drug profile →
Conditions studied
- Non-small Cell Lung Cancer — all drugs for Non-small Cell Lung Cancer →
- Small Cell Lung Cancer — all drugs for Small Cell Lung Cancer →
Sponsor
University of Southern California
Who can join
Under 39, any sex, with Non-small Cell Lung Cancer or Small Cell Lung Cancer. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
This research trial studies genomic analysis in tissue and blood samples from young patients with lung cancer. Identifying specific gene mutations (changes in deoxyribonucleic acid \[DNA\]) may help doctors tailor treatment to target the specific mutations and help plan effective treatment.
Publications & conference data
6 peer-reviewed publications reference this trial (live from Europe PMC):
-
Association Between Younger Age and Targetable Genomic Alterations and Prognosis in Non-Small-Cell Lung Cancer.
Sacher AG, Dahlberg SE, Heng J, Mach S, et al · · 2016 · cited 216× · PMID 26720421 · DOI 10.1001/jamaoncol.2015.4482 -
EGFR Fusions as Novel Therapeutic Targets in Lung Cancer.
Konduri K, Gallant JN, Chae YK, Giles FJ, et al · · 2016 · cited 96× · PMID 27102076 · DOI 10.1158/2159-8290.cd-16-0075 -
Next Generation Sequencing Technology in Lung Cancer Diagnosis.
Cainap C, Balacescu O, Cainap SS, Pop LA. · · 2021 · cited 62× · PMID 34571741 · DOI 10.3390/biology10090864 -
Unique molecular features and clinical outcomes in young patients with non-small cell lung cancer harboring ALK fusion genes.
Tian P, Liu Y, Zeng H, Tang Y, et al · · 2020 · cited 26× · PMID 31894386 · DOI 10.1007/s00432-019-03116-6 -
The Genomics of Young Lung Cancer: Comprehensive Tissue Genomic Analysis in Patients Under 40 With Lung Cancer.
Gitlitz BJ, Novello S, Vavalà T, Bittoni M, et al · · 2021 · cited 17× · PMID 34590039 · DOI 10.1016/j.jtocrr.2021.100194 -
Young lung cancer: from diagnosis to survivorship.
Florez N, Kiel L, Kaufman R, LoPiccolo J, et al · · 2025 · PMID 40641929 · DOI 10.3389/fonc.2025.1570143
Verify or expand the search:
- PubMed search for NCT02273336
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of cytology specimen collection procedure
Trials testing the same drug.
- NCT02132845 — Next Generation Sequence Target-Directed Therapy in Treating Patients With Cancer · NA · completed
- NCT02280161 — Germ-Line Mutations in Blood and Saliva Samples From Patients With Cancer · recruiting
- NCT02250404 — Molecular Signatures of Relapse in Tissue Samples From Patients With Small Cell Lung Cancer Who Are Receiving Cisplatin · withdrawn
- NCT02250352 — Core Biopsies for Establishing a Breast Tumor Tissue Repository · recruiting
- NCT01987726 — Comprehensive Gene Sequencing in Guiding Treatment Recommendations Patients With Metastatic or Recurrent Solid Tumors · completed
Other recruiting trials for Non-small Cell Lung Cancer
Currently open trials in the same condition.
- NCT07431827 — MK-3475A±Calderasib (MK-1084) in Completely Resected Stage IIA-IIIB (N2) KRAS G12Cm NSCLC (MK-1084-013) · Phase 3 · recruiting
- NCT05987956 — Pharmacogenomics IND EXEMPT SNP Clinical Trial - Alectinib and Single Nucleotide Polymorphisms · Phase 2, PHASE3 · active not recruiting
- NCT07195695 — Beamion LUNG-3: A Study to Test Whether Zongertinib Helps People With Surgically Removed, Non-small Cell Lung Cancer Wit · Phase 3 · recruiting
- NCT06686771 — Radiotherapy to Block Oligoprogression In Metastatic Non-Small-Cell Lung Cancer · Phase 3 · recruiting
- NCT06477055 — The Recurrence Gene Profiles of Adjuvant Osimertinib Therapy in Resected Non-Small-Cell Lung Cancer · recruiting
Other University of Southern California trials
Trials by the same sponsor.
- NCT07288463 — Hearing Loss and Genetic Risks for Alzheimer's Disease and Related Dementia · NA · not yet recruiting
- NCT05914233 — Non-invasive Ultrasound Retinal Stimulation for Vision Restoration · NA · not yet recruiting
- NCT06163664 — Role of ChatGPT in Vestibular Schwannoma Management · NA · withdrawn
- NCT07332312 — A Culturally Informed Patient Navigation Program (CFPN) to Reduce Delays Between Diagnosis and Treatment in American Ind · NA · not yet recruiting
- NCT07290478 — Encouraging Older Adults and Adults With Serious Illness to Designate a Health Care Proxy · NA · not yet recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT02273336 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by University of Southern California
- Last refreshed: 18 November 2021
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT02273336.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing